The clinical and cost-effectiveness of Paxlovid, RoActemra, Olumiant, Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld are discussed in a draft guidance from England’s health technology assessment institute, which says it is ready to work with the companies whose products it has not recommended.
Draft guidance on the clinical and cost-effectiveness of COVID-19 treatments in England has recommended in favor of routine commissioning for three products – Paxlovid, RoActemra and Olumiant – but has rejected five* others - Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld.
The draft guidance was published for public consultation today by the health technology assessment institute, NICE, which was asked to...
Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.
Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access
The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. However, Mark Samuels, CEO of Medicines UK, the trade body representing the off-patent industry, says companies are still face multiple hurdles in the market.
The UK drug regulator is collecting data to establish whether patients who are hospitalized for acute pancreatitis after taking a GLP-1 drug have a genetic predisposition to this side effect. If a “clear link” is found, the MHRA would consider regulatory action.
Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.
Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access
Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.
